Celcuity's Revtorpyk Becomes First Pan-PI3K/mTOR Inhibitor to Win FDA Approval, Targeting HR+/HER2− Breast Cancer Patients Without PIK3CA Mutation

Twenty years of failed attempts at the PI3K/AKT/mTOR pathway ended on July 14, 2026, when the FDA approved Celcuity Inc.'s (Nasdaq: CELC) Revtorpyk (gedatolisib) for HR+/HER2− locally advanced or metastatic breast cancer in patients without a PIK3CA mutation who have progressed on at least one line of endocrine therapy in the metastatic setting.

The approval is mechanistically singular. Revtorpyk is the only inhibitor of all four class I PI3K isoforms — α, β, δ, and γ — and both mTOR complexes, mTORC1 and mTORC2, to receive FDA clearance, per Celcuity's July 14, 2026, IR release.

CEO and co-founder Brian Sullivan put the significance in his own words: "The PI3K/AKT/mTOR, or PAM, pathway is one of the most important targets in cancer, but comprehensively inhibiting it has stymied researchers and drug developers for nearly two decades." He added: "REVTORPYK addressed this 20-year challenge by becoming the first pan-PI3K, mTORC1/2 inhibitor approved by the FDA." Both statements are drawn verbatim from Celcuity's July 14, 2026, IR release.

The Phase 3 VIKTORIA-1 trial's PIK3CA wild-type cohort produced the following results, per PharmaTitan/Celcuity data: Revtorpyk plus palbociclib and fulvestrant delivered median progression-free survival of 9.3 months versus 2.0 months for fulvestrant alone, with a hazard ratio of 0.24. The two-drug combination of Revtorpyk plus fulvestrant reached 7.4 months versus the same 2.0-month comparator, at an HR of 0.33.

The approved dosing, per a July 18, 2026, Defense World report, is 180 mg administered intravenously over 30 minutes once weekly on days one, eight, and 15 of each 28-day cycle, in combination with fulvestrant, with or without palbociclib.

The safety profile warrants attention. Stomatitis occurred in 72% of patients on the triplet regimen, alongside rash and hyperglycemia, requiring prophylactic mouthwash and glucose monitoring, per Femtech Insider's 2026 coverage.

On market size, The Insight Partners (April 28, 2026) projected the HR+/HER2− breast cancer market will grow from US$14.47 billion in 2025 to US$30.42 billion by 2034. A separate estimate from Verified Market Research (July 9, 2025) valued the market at USD$13.2 billion in 2024 and projected USD$25.3 billion by 2032, at a CAGR of 8.3% during 2026–2032. The two forecasts differ in scope and methodology.

The PIK3CA wild-type indication fills a documented gap. Existing targeted agents in the PAM pathway required PIK3CA mutations for approval, leaving patients with wild-type tumors without a pathway-directed option, according to Medical Daily.

Celcuity's commercial window is narrow but near. The company expects to launch Revtorpyk commercially in late Q3 2026, per BioSpace. Simultaneously, it plans to submit a supplemental New Drug Application in Q3 2026 seeking approval for the PIK3CA-mutated HR+/HER2− population, based on results from the mutant cohort of VIKTORIA-1 — a move that, if successful, would expand the label to cover both wild-type and mutant patients.

The broader market backdrop heading into the launch week is unsettled. The Nasdaq closed at 24,975.82 on July 24, down 0.64% on the day and off roughly 2% for the week ended July 24, per CNBC. The Federal Reserve's rate decision on July 29 and a dense earnings calendar — Apple, Qualcomm, and others reporting — will compete for investor attention.